Home > Oncology > ELCC 2022 > Advanced Non-Small Cell Lung Cancer > Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC

Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC

Presented By
Dr Edward Garon, David Geffen School of Medicine at UCLA, CA, USA
Conference
ELCC 2022
Trial
Phase 3, POSEIDON
Doi
https://doi.org/10.55788/1f78466a
The phase 3 POSEIDON study previously showed that the addition of immunotherapy (durvalumab or durvalumab/tremelimumab) to chemotherapy numerically improved survival of patients with metastatic non-small cell lung cancer (NSCLC). Patient-reported outcomes now indicate that deterioration of health-related quality of life (QoL) is delayed. Immunotherapy is an important treatment modality for metastatic NSCLC. Dual blockade of PD-1/PD-L1 and CTLA-4 pathways may provide additive or synergistic effects. In the phase 3 POSEIDON trial (NCT03164616), first-line durvalumab plus chemotherapy significantly improved progression-free survival (PFS) versus chemotherapy alone in patients with metastatic NSCLC, with a positive trend for overall survival (OS) improvement that did not reach statistical significance [1]. In addition, first-line tremelimumab plus durvalumab plus chemo...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on